Literature DB >> 23392496

BioTime acquires Geron's stem cell program.

Vicki Brower.   

Abstract

Mesh：

Year:  2013        PMID： 23392496     DOI： 10.1038/nbt0213-94a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Embryonic stem cell pioneer Geron exits field, cuts losses.

Authors:  Simon Frantz
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908
  1 in total
  3 in total

Review 1.  From bench to FDA to bedside: US regulatory trends for new stem cell therapies.

Authors:  Paul S Knoepfler
Journal:  Adv Drug Deliv Rev       Date:  2014-12-07       Impact factor: 15.470

Review 2.  Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers.

Authors:  Shibani Pati; Marcello Pilia; Juanita M Grimsley; Alexia T Karanikas; Blessing Oyeniyi; John B Holcomb; Andrew P Cap; Todd E Rasmussen
Journal:  Shock       Date:  2015-12       Impact factor: 3.454

3.  Cellular therapies in trauma and critical care medicine: Looking towards the future.

Authors:  Shibani Pati; Todd E Rasmussen
Journal:  PLoS Med       Date:  2017-07-11       Impact factor: 11.069
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.